ZA200500205B - Novel pierazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders - Google Patents
Novel pierazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders Download PDFInfo
- Publication number
- ZA200500205B ZA200500205B ZA200500205A ZA200500205A ZA200500205B ZA 200500205 B ZA200500205 B ZA 200500205B ZA 200500205 A ZA200500205 A ZA 200500205A ZA 200500205 A ZA200500205 A ZA 200500205A ZA 200500205 B ZA200500205 B ZA 200500205B
- Authority
- ZA
- South Africa
- Prior art keywords
- ethyl
- pyrazinone
- piperazinyl
- alkyl
- aryl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 22
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 title description 3
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 81
- 125000001072 heteroaryl group Chemical group 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 55
- 150000002367 halogens Chemical class 0.000 claims description 51
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- -1 3- pyridyloxy, 6-methyl-2-nitro-3-pyridyloxy Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 21
- 125000005110 aryl thio group Chemical group 0.000 claims description 19
- 125000004104 aryloxy group Chemical group 0.000 claims description 19
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 19
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 206010046543 Urinary incontinence Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 206010006482 Bronchospasm Diseases 0.000 claims description 6
- 208000002249 Diabetes Complications Diseases 0.000 claims description 6
- 206010012655 Diabetic complications Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 6
- 125000001769 aryl amino group Chemical group 0.000 claims description 6
- 230000007885 bronchoconstriction Effects 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000003176 neuroleptic agent Substances 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 230000001732 thrombotic effect Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 150000001204 N-oxides Chemical group 0.000 claims description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 206010022437 insomnia Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000651 prodrug Chemical group 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 230000036299 sexual function Effects 0.000 claims description 5
- 201000009032 substance abuse Diseases 0.000 claims description 5
- 231100000736 substance abuse Toxicity 0.000 claims description 5
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 5
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010022562 Intermittent claudication Diseases 0.000 claims description 4
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 4
- 206010067013 Normal tension glaucoma Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 206010047163 Vasospasm Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000014679 binge eating disease Diseases 0.000 claims description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001076 chlorpromazine Drugs 0.000 claims description 4
- 238000002651 drug therapy Methods 0.000 claims description 4
- 229960003878 haloperidol Drugs 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000002978 low tension glaucoma Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 201000002859 sleep apnea Diseases 0.000 claims description 4
- JORXUVJJSXEKFA-UHFFFAOYSA-N 1-benzyl-3-(4-methylpiperazin-1-yl)quinoxalin-2-one Chemical compound C1CN(C)CCN1C(C1=O)=NC2=CC=CC=C2N1CC1=CC=CC=C1 JORXUVJJSXEKFA-UHFFFAOYSA-N 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 150000002989 phenols Chemical class 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- IGHQRQSGOLMKFL-UHFFFAOYSA-N 1-(2-phenylsulfanylethyl)-3-piperazin-1-ylpyrazin-2-one Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCSC1=CC=CC=C1 IGHQRQSGOLMKFL-UHFFFAOYSA-N 0.000 claims description 2
- WVIJXDWAPZYZJJ-UHFFFAOYSA-N 1-[2-(1,3-benzodioxol-5-yloxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound N=1C=CN(CCOC=2C=C3OCOC3=CC=2)C(=O)C=1N1CCNCC1 WVIJXDWAPZYZJJ-UHFFFAOYSA-N 0.000 claims description 2
- YOKQAQBNCZWOIY-UHFFFAOYSA-N 1-[2-(3-methoxyphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound COC1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 YOKQAQBNCZWOIY-UHFFFAOYSA-N 0.000 claims description 2
- MBZJWCPXTQHUGS-UHFFFAOYSA-N 1-[2-(4-bromophenoxy)ethyl]-3-(3-methylpiperazin-1-yl)pyrazin-2-one Chemical compound C1CNC(C)CN1C(C1=O)=NC=CN1CCOC1=CC=C(Br)C=C1 MBZJWCPXTQHUGS-UHFFFAOYSA-N 0.000 claims description 2
- GSQWUGXDBPINHO-UHFFFAOYSA-N 1-[2-(4-bromophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound C1=CC(Br)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 GSQWUGXDBPINHO-UHFFFAOYSA-N 0.000 claims description 2
- LNXMJTLNDDARTM-UHFFFAOYSA-N 1-[2-(4-cyclopentylphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCOC(C=C1)=CC=C1C1CCCC1 LNXMJTLNDDARTM-UHFFFAOYSA-N 0.000 claims description 2
- QGOVGQGLRDXJKE-UHFFFAOYSA-N 1-[2-(4-phenoxyphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCOC(C=C1)=CC=C1OC1=CC=CC=C1 QGOVGQGLRDXJKE-UHFFFAOYSA-N 0.000 claims description 2
- WFCXZUSIGVDCTC-UHFFFAOYSA-N 1-[2-[3-(dimethylamino)phenoxy]ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound CN(C)C1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 WFCXZUSIGVDCTC-UHFFFAOYSA-N 0.000 claims description 2
- FHBKPVUXFBHWTN-UHFFFAOYSA-N 1-[3-(4-fluorophenyl)-3-oxopropyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCN1C(=O)C(N2CCNCC2)=NC=C1 FHBKPVUXFBHWTN-UHFFFAOYSA-N 0.000 claims description 2
- YODZJNDAOARSDN-UHFFFAOYSA-N 2-[2-(2-oxo-3-piperazin-1-ylpyrazin-1-yl)ethoxy]benzonitrile Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCOC1=CC=CC=C1C#N YODZJNDAOARSDN-UHFFFAOYSA-N 0.000 claims description 2
- GRJURQLVFWUXLS-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)-1-[2-(4-fluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1=CC(F)=CC=C1OCCN1C(=O)C(N2CCNCCC2)=NC=C1 GRJURQLVFWUXLS-UHFFFAOYSA-N 0.000 claims description 2
- NJNVPRVTSFDBFP-UHFFFAOYSA-N 3-(3-methylpiperazin-1-yl)-1-(2-phenoxyethyl)pyrazin-2-one Chemical compound C1CNC(C)CN1C(C1=O)=NC=CN1CCOC1=CC=CC=C1 NJNVPRVTSFDBFP-UHFFFAOYSA-N 0.000 claims description 2
- CXZHZJMSSSMCNU-UHFFFAOYSA-N 3-(3-methylpiperazin-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1CNC(C)CN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F CXZHZJMSSSMCNU-UHFFFAOYSA-N 0.000 claims description 2
- JXGGRLBIMUPSHM-UHFFFAOYSA-N 3-(3-methylpiperazin-1-yl)-1-[2-[4-(trifluoromethyl)phenoxy]ethyl]pyrazin-2-one Chemical compound C1CNC(C)CN1C(C1=O)=NC=CN1CCOC1=CC=C(C(F)(F)F)C=C1 JXGGRLBIMUPSHM-UHFFFAOYSA-N 0.000 claims description 2
- GMWJQTKXYXVCLK-UHFFFAOYSA-N 3-(4-benzylpiperazin-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one;hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC(F)=C1OCCN1C(=O)C(N2CCN(CC=3C=CC=CC=3)CC2)=NC=C1 GMWJQTKXYXVCLK-UHFFFAOYSA-N 0.000 claims description 2
- GJPYZWFOYPZLRL-UHFFFAOYSA-N 3-(4-butylpiperazin-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1CN(CCCC)CCN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F GJPYZWFOYPZLRL-UHFFFAOYSA-N 0.000 claims description 2
- BCHHCGWKCZNQIU-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1CN(C)CCN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F BCHHCGWKCZNQIU-UHFFFAOYSA-N 0.000 claims description 2
- WFGRKDDSJAQRDJ-UHFFFAOYSA-N 3-(4-propan-2-ylpiperazin-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1CN(C(C)C)CCN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F WFGRKDDSJAQRDJ-UHFFFAOYSA-N 0.000 claims description 2
- ZZSQCJCURHYKEQ-UHFFFAOYSA-N 3-[4-(2-methoxyethyl)piperazin-1-yl]-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1CN(CCOC)CCN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F ZZSQCJCURHYKEQ-UHFFFAOYSA-N 0.000 claims description 2
- XSKYHZYWGSOTMJ-UHFFFAOYSA-N 3-piperazin-1-yl-1-[(2,4,5-trifluorophenyl)methyl]pyrazin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1CN1C(=O)C(N2CCNCC2)=NC=C1 XSKYHZYWGSOTMJ-UHFFFAOYSA-N 0.000 claims description 2
- MWEAXOGWHUSQBL-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-(2,3,4-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound FC1=C(F)C(F)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 MWEAXOGWHUSQBL-UHFFFAOYSA-N 0.000 claims description 2
- WGHXRGUSQHHKHR-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 WGHXRGUSQHHKHR-UHFFFAOYSA-N 0.000 claims description 2
- POKHFNQSMXNJPF-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-[3-(trifluoromethyl)phenoxy]ethyl]pyrazin-2-one Chemical compound FC(F)(F)C1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 POKHFNQSMXNJPF-UHFFFAOYSA-N 0.000 claims description 2
- 238000007126 N-alkylation reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- FHFZAOQCQDXLQS-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-piperazin-1-ylpyrazin-2-one Chemical compound N=1C=CN(CC2OC3=CC=CC=C3OC2)C(=O)C=1N1CCNCC1 FHFZAOQCQDXLQS-UHFFFAOYSA-N 0.000 claims 1
- PUPXUOWSXIWPTO-UHFFFAOYSA-N 1-(2-phenoxyethyl)-3-piperazin-1-ylpyrazin-2-one Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCOC1=CC=CC=C1 PUPXUOWSXIWPTO-UHFFFAOYSA-N 0.000 claims 1
- VLKGLOPWUKTOEB-UHFFFAOYSA-N 1-[2-(2,3-dichlorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound ClC1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1Cl VLKGLOPWUKTOEB-UHFFFAOYSA-N 0.000 claims 1
- DZKARFXILDWIQB-UHFFFAOYSA-N 1-[2-(2,4-difluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound FC1=CC(F)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 DZKARFXILDWIQB-UHFFFAOYSA-N 0.000 claims 1
- KMJOAHSKEJFPHI-UHFFFAOYSA-N 1-[2-(2,6-difluorophenoxy)ethyl]-3-(3-methylpiperazin-1-yl)pyrazin-2-one Chemical compound C1CNC(C)CN1C(C1=O)=NC=CN1CCOC1=C(F)C=CC=C1F KMJOAHSKEJFPHI-UHFFFAOYSA-N 0.000 claims 1
- RUVAFNORGZUDJA-UHFFFAOYSA-N 1-[2-(2,6-difluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound FC1=CC=CC(F)=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 RUVAFNORGZUDJA-UHFFFAOYSA-N 0.000 claims 1
- IIAYMQKSZLDQMH-UHFFFAOYSA-N 1-[2-(2-methylphenyl)sulfanylethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound CC1=C(SCCN2C(C(=NC=C2)N2CCNCC2)=O)C=CC=C1 IIAYMQKSZLDQMH-UHFFFAOYSA-N 0.000 claims 1
- IPHAXJVPUYWAKL-UHFFFAOYSA-N 1-[2-(3,5-difluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound FC1=CC(F)=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 IPHAXJVPUYWAKL-UHFFFAOYSA-N 0.000 claims 1
- JYNVJZPOALDEJO-UHFFFAOYSA-N 1-[2-(3-butoxyphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound CCCCOC1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 JYNVJZPOALDEJO-UHFFFAOYSA-N 0.000 claims 1
- NPHXIQQRXUFAPU-UHFFFAOYSA-N 1-[2-(3-hydroxyphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound OC1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 NPHXIQQRXUFAPU-UHFFFAOYSA-N 0.000 claims 1
- CYRGMANRUCHIRU-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1OCCN1C(=O)C(N2CCNCCC2)=NC=C1 CYRGMANRUCHIRU-UHFFFAOYSA-N 0.000 claims 1
- WIEAFBNEKGMWGG-UHFFFAOYSA-N 3-[4-(2-phenylethyl)piperazin-1-yl]-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC(F)=C1OCCN1C(=O)C(N2CCN(CCC=3C=CC=CC=3)CC2)=NC=C1 WIEAFBNEKGMWGG-UHFFFAOYSA-N 0.000 claims 1
- GDMHVMCEETVZLB-UHFFFAOYSA-N 3-piperazin-1-yl-1-(2-quinoxalin-6-yloxyethyl)pyrazin-2-one Chemical compound N=1C=CN(CCOC=2C=C3N=CC=NC3=CC=2)C(=O)C=1N1CCNCC1 GDMHVMCEETVZLB-UHFFFAOYSA-N 0.000 claims 1
- HGOGTCLPZAHMOD-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-(5,6,7,8-tetrahydronaphthalen-2-yloxy)ethyl]pyrazin-2-one Chemical compound N=1C=CN(CCOC=2C=C3CCCCC3=CC=2)C(=O)C=1N1CCNCC1 HGOGTCLPZAHMOD-UHFFFAOYSA-N 0.000 claims 1
- DWKYGDOUCKUEFK-UHFFFAOYSA-N 3-piperazin-1-yl-1-[3-(2,4,5-trifluorophenoxy)propyl]pyrazin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1OCCCN1C(=O)C(N2CCNCC2)=NC=C1 DWKYGDOUCKUEFK-UHFFFAOYSA-N 0.000 claims 1
- ZUVXGGOTOKUKGY-UHFFFAOYSA-N 3-piperazin-1-yl-1-[4-(2,4,5-trifluorophenoxy)butyl]pyrazin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1OCCCCN1C(=O)C(N2CCNCC2)=NC=C1 ZUVXGGOTOKUKGY-UHFFFAOYSA-N 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- VCPZUTGPISLSEU-GFCCVEGCSA-N tert-butyl (3r)-4-[3-(2-hydroxyethoxy)pyrazin-2-yl]-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1C1=NC=CN=C1OCCO VCPZUTGPISLSEU-GFCCVEGCSA-N 0.000 claims 1
- SFTWEUWTIPMNNR-UHFFFAOYSA-N tert-butyl 4-[3-(2-hydroxyethoxy)pyrazin-2-yl]-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1C1=NC=CN=C1OCCO SFTWEUWTIPMNNR-UHFFFAOYSA-N 0.000 claims 1
- PHDHXIFLYDUZOR-UHFFFAOYSA-N tert-butyl 4-[3-(2-hydroxyethoxy)pyrazin-2-yl]-2-methylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)C(C)CN1C1=NC=CN=C1OCCO PHDHXIFLYDUZOR-UHFFFAOYSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229950005789 sarpogrelate Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- AIUOUEPKBRDPLG-UHFFFAOYSA-N 1,3-benzoxathiole Chemical compound C1=CC=C2SCOC2=C1 AIUOUEPKBRDPLG-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- XMUYNBYPANDDKJ-UHFFFAOYSA-N 1-(3-oxo-3-phenylpropyl)-3-piperazin-1-ylpyrazin-2-one Chemical compound C=1C=CC=CC=1C(=O)CCN(C1=O)C=CN=C1N1CCNCC1 XMUYNBYPANDDKJ-UHFFFAOYSA-N 0.000 description 1
- IWLVBOQWDODDOC-UHFFFAOYSA-N 1-[2-(1h-indol-3-yl)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound N=1C=CN(CCC=2C3=CC=CC=C3NC=2)C(=O)C=1N1CCNCC1 IWLVBOQWDODDOC-UHFFFAOYSA-N 0.000 description 1
- LYPBDFAXLYBXJG-UHFFFAOYSA-N 1-[2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound N=1C=CN(CCOC=2C=3OCCOC=3C=CC=2)C(=O)C=1N1CCNCC1 LYPBDFAXLYBXJG-UHFFFAOYSA-N 0.000 description 1
- BBVMESKJOHGYCV-UHFFFAOYSA-N 1-[2-(3-benzoylphenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound C=1C=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=CC=1C(=O)C1=CC=CC=C1 BBVMESKJOHGYCV-UHFFFAOYSA-N 0.000 description 1
- YKSALSOHQPOEGF-UHFFFAOYSA-N 1-[2-(3-fluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound FC1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 YKSALSOHQPOEGF-UHFFFAOYSA-N 0.000 description 1
- NIZBYWZNNMPQOP-UHFFFAOYSA-N 1-[2-(3-nitrophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound [O-][N+](=O)C1=CC=CC(OCCN2C(C(N3CCNCC3)=NC=C2)=O)=C1 NIZBYWZNNMPQOP-UHFFFAOYSA-N 0.000 description 1
- COOUQPRZIVNLTM-UHFFFAOYSA-N 1-[2-(4-chloro-2-fluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound FC1=CC(Cl)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 COOUQPRZIVNLTM-UHFFFAOYSA-N 0.000 description 1
- HVUGHSWNBQKYSL-UHFFFAOYSA-N 1-[2-(4-fluorophenoxy)ethyl]-3-piperazin-1-ylpyrazin-2-one Chemical compound C1=CC(F)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 HVUGHSWNBQKYSL-UHFFFAOYSA-N 0.000 description 1
- VVYHLRRCCGWGCV-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-3-piperazin-1-ylquinoxalin-2-one Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N=C1N1CCNCC1 VVYHLRRCCGWGCV-UHFFFAOYSA-N 0.000 description 1
- CDDDRVNOHLVEED-UHFFFAOYSA-N 1-cyclohexyl-3-[1-[[1-(cyclohexylcarbamoylamino)cyclohexyl]diazenyl]cyclohexyl]urea Chemical compound C1CCCCC1(N=NC1(CCCCC1)NC(=O)NC1CCCCC1)NC(=O)NC1CCCCC1 CDDDRVNOHLVEED-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- CDYQSZXMIZBJFL-UHFFFAOYSA-N 1-methyl-3-piperazin-1-ylquinoxalin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2N=C1N1CCNCC1 CDYQSZXMIZBJFL-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AYTPIVIDHMVGSX-UHFFFAOYSA-N 2,1,3-benzoselenadiazole Chemical compound C1=CC=CC2=N[se]N=C21 AYTPIVIDHMVGSX-UHFFFAOYSA-N 0.000 description 1
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- NHSOOAWURRKYMM-UHFFFAOYSA-N 2,3-dihydro-1,4-benzoxathiine Chemical compound C1=CC=C2OCCSC2=C1 NHSOOAWURRKYMM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- DNCBINCWTHXVOD-UHFFFAOYSA-N 2-pyrazin-2-yloxypyrazine Chemical class C=1N=CC=NC=1OC1=CN=CC=N1 DNCBINCWTHXVOD-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- JJBXPFRTXHADRQ-UHFFFAOYSA-N 2h-1,5-benzoxathiepine Chemical class S1C=CCOC2=CC=CC=C21 JJBXPFRTXHADRQ-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- QQVXDMFULJVZLA-UHFFFAOYSA-N 3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine Chemical compound C1=CN=C2NCCOC2=C1 QQVXDMFULJVZLA-UHFFFAOYSA-N 0.000 description 1
- BRHGMKLFSCZGAX-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)-1-[2-(4-propan-2-ylphenoxy)ethyl]pyrazin-2-one Chemical compound C1=CC(C(C)C)=CC=C1OCCN1C(=O)C(N2CCNCCC2)=NC=C1 BRHGMKLFSCZGAX-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FKFNPTZCZKTCNF-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-1h-quinoxalin-2-one Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC1=O FKFNPTZCZKTCNF-UHFFFAOYSA-N 0.000 description 1
- LKHRUCCZSRGDIM-LLVKDONJSA-N 3-[(2r)-2-methylpiperazin-1-yl]-1-[2-(2,4,5-trifluorophenoxy)ethyl]pyrazin-2-one Chemical compound C[C@@H]1CNCCN1C(C1=O)=NC=CN1CCOC1=CC(F)=C(F)C=C1F LKHRUCCZSRGDIM-LLVKDONJSA-N 0.000 description 1
- MRQYVAQOLKPVQQ-UHFFFAOYSA-N 3-piperazin-1-yl-1-(2-thiophen-3-ylethyl)pyrazin-2-one Chemical compound O=C1C(N2CCNCC2)=NC=CN1CCC=1C=CSC=1 MRQYVAQOLKPVQQ-UHFFFAOYSA-N 0.000 description 1
- FSGYJLUHCVLSKT-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-(2,4,5-trifluorophenoxy)ethyl]quinoxalin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1OCCN1C(=O)C(N2CCNCC2)=NC2=CC=CC=C21 FSGYJLUHCVLSKT-UHFFFAOYSA-N 0.000 description 1
- NPCGSSZJYZXMJX-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-(4-propan-2-ylphenoxy)ethyl]pyrazin-2-one Chemical compound C1=CC(C(C)C)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 NPCGSSZJYZXMJX-UHFFFAOYSA-N 0.000 description 1
- CSAOLOZXVRFPFS-UHFFFAOYSA-N 3-piperazin-1-yl-1-[2-[4-(trifluoromethyl)phenoxy]ethyl]pyrazin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1OCCN1C(=O)C(N2CCNCC2)=NC=C1 CSAOLOZXVRFPFS-UHFFFAOYSA-N 0.000 description 1
- VBHKPSBTQOQTHK-UHFFFAOYSA-N 3-piperazin-1-yl-1h-quinoxalin-2-one Chemical compound O=C1NC2=CC=CC=C2N=C1N1CCNCC1 VBHKPSBTQOQTHK-UHFFFAOYSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229950000388 amperozide Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- NUFBIWXQVQWZNH-UHFFFAOYSA-N methyl 7-methoxy-3-oxo-1,5-benzoxathiepine-4-carboxylate Chemical compound O1CC(=O)C(C(=O)OC)SC2=CC(OC)=CC=C21 NUFBIWXQVQWZNH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N tetrahydroquinoline Natural products C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202287A SE0202287D0 (sv) | 2002-07-19 | 2002-07-19 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200500205B true ZA200500205B (en) | 2006-07-26 |
Family
ID=20288606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200500205A ZA200500205B (en) | 2002-07-19 | 2005-01-10 | Novel pierazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP4831966B2 (xx) |
EA (1) | EA007539B1 (xx) |
SE (1) | SE0202287D0 (xx) |
SI (1) | SI1534391T1 (xx) |
ZA (1) | ZA200500205B (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2008129679A (ru) * | 2005-12-21 | 2010-01-27 | Янссен Фармацевтика Н.В. (Be) | Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI193974A (xx) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
SE421695B (sv) * | 1975-04-21 | 1982-01-25 | Merck & Co Inc | Sett att framstella piperazinylpyraziner |
US4163849A (en) * | 1978-03-17 | 1979-08-07 | Merck & Co., Inc. | Piperazinylpyrazines |
ZA954689B (en) * | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
DE60024986T2 (de) * | 1999-05-21 | 2006-07-27 | Biovitrum Ab | Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung |
-
2002
- 2002-07-19 SE SE0202287A patent/SE0202287D0/xx unknown
-
2003
- 2003-06-25 JP JP2004522879A patent/JP4831966B2/ja not_active Expired - Fee Related
- 2003-06-25 EA EA200500235A patent/EA007539B1/ru not_active IP Right Cessation
- 2003-06-25 SI SI200330754T patent/SI1534391T1/sl unknown
-
2005
- 2005-01-10 ZA ZA200500205A patent/ZA200500205B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA007539B1 (ru) | 2006-10-27 |
SI1534391T1 (sl) | 2007-06-30 |
SE0202287D0 (sv) | 2002-07-19 |
JP2005533847A (ja) | 2005-11-10 |
EA200500235A1 (ru) | 2005-08-25 |
JP4831966B2 (ja) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2449899C (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor | |
US7229997B2 (en) | Compounds and their use | |
JP2008050365A (ja) | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 | |
US7244722B2 (en) | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | |
ZA200500205B (en) | Novel pierazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders | |
AU2002215294B2 (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor | |
US6756377B2 (en) | Compounds and their use | |
AU2002215294A1 (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor | |
JPH01221361A (ja) | ピペラジン化合物 |